Increased safety for prefilled syringes

Ravensburg, (PresseBox) - Vetter Pharma-Fertigung GmbH & Co. KG announce the launch of a new closure system for pre-filled syringes that will enable a greater degree of safety for users. The Vetter V-OVS NS® was designed for syringes with a staked needle. It features mechanisms to prevent tampering, counterfeiting. The closure system will be showcased at the ISCE in Milan, October 2-4.

The V-OVS NS® fits on a 1 ml-long glass-barrel syringe. It consists of a sealing ring and a protective cap of solid plastic with a needle protection element of soft rubber. Removing the cap breaks the seal, indicating that the syringe has been used or manipulated. The cap itself is made of hard plastic, which considerably reduces the risk of injuries from the needle itself.

The V-OVS NS® was created by Vetter in response to the needs of patients, medical personnel and the pharmaceutical industry. “It’s a real benefit for all concerned,” says Dr. Paul Nelles, Director of Vetter Development Services. “Patients now know that they are receiving the genuine product and accidental injuries with needles will be greatly reduced. It was vital that we think ahead and consult with our customers.” In addition, the V-OVS NS® will allow for faster time to market for pharmaceutical companies, since it complies with anti-counterfeiting regulations.

Vetter Pharma International GmbH

Vetter is an independent international specialist in the production of aseptically pre-filled syringe systems, cartridges and vials with FDA-approved clients’ products and processes.

Press releases you might also be interested in

Weitere Informationen zum Thema "Medizintechnik":

Mobiler Flugbegleiter CIMON fliegt zur ISS

Der in­ter­ak­ti­ve Flu­gas­sis­tent CI­MON (Cr­ew In­ter­ac­ti­ve Mo­bi­le Com­pa­ni­on) soll ab Früh­som­mer 2018 die Cr­ew auf der Raum­sta­ti­on ISS un­ter­stüt­zen.


Subscribe for news

The subscribtion service of the PresseBox informs you about press information of a certain topic by your choice at a choosen time. Please enter your email address to receive the email with the press releases.

An error occurred!

Thank you! You will receive a confirmation email within a few minutes.

I want to subscribe to the gratis press mail and have read and accepted the conditions.